News
The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus ... treat various cancer indications and rheumatoid arthritis. The CHMP backed approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback